Early strategic decisions
Compare more assets and indications before you narrow the field.
For Search & Evaluate, portfolio strategy, corporate strategy, and investment teams.
For biopharma portfolio, strategy, and intelligence teams.
Research for biopharma strategy.
Epistemic AI uses agents to gather, connect, and update research for biopharma strategy. Life-science experts review the evidence, analysis, and conclusions. You choose the format.
Our clients already include 4 of the largest pharmaceutical companies.
Illustrative strategic deliverable
Decision context
Which programs change the portfolio priority?
Clinical trials
Congress abstracts
Regulatory sources
Portfolio implication
Evidence changes the priority—not just the
summary.
Program A moves to active monitoring; Program B requires an evidence-gap review.
Evidence register
Every conclusion remains traceable.
Evidence current through the agreed review cycle
The decision problem
Manual research forces teams to make narrow decisions early.
Each new asset, indication, competitor, or scenario can trigger another months-long project. Teams examine fewer options, then receive analysis that starts aging as soon as it arrives.
Established CI programs
Keep competitive landscapes current as programs, catalysts, and evidence change.
For competitive-intelligence and commercial-strategy teams that need current, reusable analysis.
What clients can buy today
Finished analysis, ready to use.
Bring us the strategic question. We deliver the analysis in the formats your team uses—and, when scoped, keep it current for you.
Interactive dashboard
Detailed report
Executive deck
Structured output
Competitive and portfolio intelligence
See where competitor programs are moving, which catalysts matter, where evidence gaps remain, and what that means for your portfolio.
Landscapes · asset profiles · trial matrices · strategic implications
Strategic deliverable
Competitive landscape
Strategic implications · evidence
register
View deliverables
Target product profiles
Build an evidence-backed target product profile against clinical, competitive, regulatory, and market benchmarks.
Structured TPPs · benchmarks · positioning · strategic options
Strategic deliverable
Structured TPP
Evidence appendix · strategic options
View deliverables
Conference and evidence intelligence
See what changed at a conference, why it matters, and what deserves attention next.
Readiness materials · executive summaries · evidence updates · implications
Strategic deliverable
Readiness deck
Evidence register · executive summary
View deliverables
Selected engagements
From one engagement to an ongoing intelligence program.
Three examples of a focused first engagement becoming a broader, repeatable program.
Top-20 pharma · Global RWE
Scale
30+
conferences supported each year
A conference-intelligence project became repeatable
Automated extraction, classification, and thematic analysis now support repeatable readiness work across therapeutic areas.
Strategic deliverable Readiness packs and evidence updates
Top-20 pharma · Strategic analytics
Documented delivery
Months → days
Then expanded from an initial TPP pilot
A TPP pilot became a multi-phase workflow
Complete structured TPPs replaced a slow, inconsistent manual process and expanded beyond the initial engagement.
Strategic deliverable Structured TPPs and strategic options
Mid-size pharma · Oncology
Expansion
Portfolio-wide
Expanded from one oncology indication
One oncology landscape expanded across the portfolio
The work expanded into TPPs, conference intelligence, target identification, and portfolio-level trend analysis.
Strategic deliverable Landscapes and portfolio analysis
“Days, not months” reflects a documented target product profile engagement. Delivery timing depends on scope, evidence availability, and review requirements.